Current treatment options for hereditary angioedema due to C1 inhibitor deficiency

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 1, 2016, Pages 27-40

  Wu, Maddalena Alessandra ^a   Zanichelli, Andrea ^a   Mansi, Marta ^a   Cicardi, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

angioedema; bradykinin; C1 inhibitor; ecallantide; icatibant; kallikrein

Indexed keywords

AMINOCAPROIC ACID; COMPLEMENT COMPONENT C1S INHIBITOR; CREATINE KINASE; DANAZOL; ECALLANTIDE; FRESH FROZEN PLASMA; HIGH DENSITY LIPOPROTEIN; ICATIBANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLTESTOSTERONE; STANOZOLOL; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT; BRADYKININ B2 RECEPTOR ANTAGONIST; PLASMA KALLIKREIN; RECOMBINANT PROTEIN; SERPING1 PROTEIN, HUMAN;

ABDOMINAL PAIN; ALLERGIC REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHENIA; BURNING SENSATION; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DRUG ADSORPTION; DRUG FEVER; DRUG PURIFICATION; DRUG SAFETY; ERYTHEMA; FATIGUE; HEADACHE; HUMAN; MENSTRUAL IRREGULARITY; MYALGIA; NAUSEA; PATHOGENESIS; PERSONAL EXPERIENCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA; PRECIPITATION; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; URTICARIA; VOMITING; ANGIOEDEMAS, HEREDITARY; ANTAGONISTS AND INHIBITORS; DISEASE MANAGEMENT; METABOLISM;

ANGIOEDEMAS, HEREDITARY; ANTIFIBRINOLYTIC AGENTS; BRADYKININ B2 RECEPTOR ANTAGONISTS; COMPLEMENT C1 INACTIVATOR PROTEINS; DISEASE MANAGEMENT; HUMANS; PLASMA; PLASMA KALLIKREIN; RECOMBINANT PROTEINS;

EID: 84955628881     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2016.1104300     Document Type: Review

References (96)

1. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: Consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69:602-616.
2. Zanichelli A, Arcoleo F, Barca M, et al. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy. Orphanet J Rare Dis. 2015;10:11.
3. Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet. 2012;379:474-481.
4. Bafunno V, Bova M, Loffredo S, et al. Mutational spectrum of the c1 inhibitor gene in a cohort of Italian patients with hereditary angioedema: Description of nine novel mutations. Ann Hum Genet. 2014;78:73-82.
5. C1 inhibitor gene mutation database. Available from: Http://hae.enzim.hu/stat.php.
6. Caballero T, Aygoren-Pursun E, Bygum A, et al. The humanistic burden of hereditary angioedema: Results from the Burden of Illness Study in Europe. Allergy Asthma Proc. 2014;35:47-53.
7. Bock SC, Skriver K, Nielsen E, et al. Human C1 inhibitor: Primary structure, cDNA cloning, and chromosomal localization. Biochemistry. 1986;25:4292-4301.
8. Carter PE, Dunbar B, Fothergill JE. Genomic and cDNA cloning of the human C1 inhibitor. Intron-exon junctions and comparison with other serpins. Eur J Biochem. 1988;173:163-169.
9. Davis AE 3rd, Whitehead AS, Harrison RA, et al. Human inhibitor of the first component of complement, C1: Characterization of cDNA clones and localization of the gene to chromosome 11. Proc Natl Acad Sci USA. 1986;83:3161-3165.
10. Davis AE 3rd, Mejia P, Lu F. Biological activities of C1 inhibitor. Mol Immunol. 2008;45:4057-4063.
11. Kaplan AP, Joseph K. The bradykininforming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:193-204.
12. Fields T, Ghebrehiwet B, Kaplan AP. Kinin formation in hereditary angioedema plasma: Evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. J Allergy Clin Immunol. 1983;72:54-60.
13. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693-1697.
14. De Maat S, Tersteeg C, Herczenik E, et al. Tracking down contact activation-from coagulation in vitro to inflammation in vivo. Int J Lab Hematol. 2014;36:374-381.
15. Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002;109:1057-1063.
16. Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol. 2007;119:1497-1503.
17. Bossi F, Fischetti F, Regoli D, et al. Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol. 2009;124:1303-10.e1304.
18. Magerl M, Bader M, Gompel A, et al. Bradykinin in health and disease: Proceedings of the Bradykinin Symposium 2012 Berlin 23-24 August 2012. Inflamm Res. 2014;63(3):173-178.
19. Cugno M, Zanichelli A, Foieni F, et al. C1-inhibitor deficiency and angioedema: Molecular mechanisms and clinical progress. Trends Mol Med. 2009;15:69-78. DOI:10.1016/j.molmed.2008.12.001.
20. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med. 2002;347:621-622.
21. Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group. Allergy. 2012;67:147-157.
22. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012;130:692-697.
23. Pickering RJ, Good RA, Kelly JR, et al. Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet. 1969;1:326-330.
24. Vogelaar EF, Brummelhuis HG, Krijnen HW. Contributions to the optimal use of human blood. 3. Large-scale preparation of human c1 esterase inhibitor concentrate for clinical use. Vox Sang. 1974;26:118-127.
25. Williams C, Wickerhauser M, Busby TF, et al. Pasteurization of C1 inactivator in the presence of citrate salts. Vox Sang. 1984;46:260-269.
26. Soluk L, Price H, Sinclair C, et al. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: Enhanced nanofiltration and manufacturing process overview. Am J Ther. 2008;15:435-443.
27. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124:801-808.
28. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363:513-522.
29. Craig TJ, Bewtra AK, Bahna SL, et al. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks-final results of the I.M.P.A.C.T.2 study. Allergy. 2011;66:1604-1611.
30. Riedl MA, Hurewitz DS, Levy R, et al. Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: An open-label trial. Ann Allergy Asthma Immunol. 2012;108:49-53.
31. Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129:308-320.
32. Cicardi M, Zingale LC, Zanichelli A. A patient with hereditary angioedema who experienced anaphylaxis in response to C1 esterase inhibitor is successfully treated with DX-88 (Ecallantide), a potent human plasma kallikrein inhibitor: A case study. Mol Immunol. 2007;44:160-161.
33. Cicardi M, Mannucci PM, Castelli R, et al. Reduction in transmission of hepatitis C after the introduction of a heattreatment step in the production of C1-inhibitor concentrate. Transfusion. 1995;35:209-212.
34. De Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: A review. Transfus Apher Sci. 2003;29:247-254.
35. Groner A, Nowak T, Schafer W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion. 2012;52:2104-2112.
36. Soucie JM, De Staercke C, Monahan PE, et al. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. Transfusion. 2013;53:1217-1225.
37. Crowther M, Bauer KA, Kaplan AP. The thrombogenicity of C1 esterase inhibitor (human): Review of the evidence. Allergy Asthma Proc. 2014;35(6):444-453.
38. Van Doorn MB, Burggraaf J, Van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol. 2005;116:876-883.
39. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126:821-7. e814.
40. Moldovan D, Reshef A, Fabiani J, et al. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European openlabel extension study. Clin Exp Allergy. 2012;42:929-935.
41. Riedl MA, Levy RJ, Suez D, et al. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: A North American open-label study. Ann Allergy Asthma Immunol. 2013;110:295-299.
42. Riedl MA, Bernstein JA, Li H, et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: Phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2014;112:163-9.e161.
43. Farrell C, Hayes S, Relan A, et al. Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. Br J Clin Pharmacol. 2013;76:897-907.
44. Hack CE, Relan A, Van Amersfoort ES, et al. Target levels of functional C1-inhibitor in hereditary angioedema. Allergy. 2012;67:123-130.
45. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363:532-541.
46. Malbran A, Riedl M, Ritchie B, et al. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial. Clin Exp Immunol. 2014;177:544-553.
47. Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B? receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: The FAST-3 trial. Ann Allergy Asthma Immunol. 2011;107(6):529-537.
48. Malbran A. Successful treatment of 103 attacks of hereditary angioedema (HAE) with bradykinin B2 receptor antagonist icatibant. J Allergy Clin Immunol. 2008;121:S102.
49. Sheffer AL, Campion M, Levy RJ, et al. Ecallantide (DX-88) for acute hereditary angioedema attacks: Integrated analysis of 2 double-blind, phase 3 studies. J Allergy Clin Immunol. 2011;128:153-9 e154.
50. Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: A phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:523-529.
51. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363:523-531.
52. Craig TJ, Li HH, Riedl M, et al. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2015;3:206-12.e4.
53. Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol. 2007;98:383-388.
54. Tuong LA, Olivieri K, Craig TJ. Barriers to self-administered therapy for hereditary angioedema. Allergy Asthma Proc. 2014;35:250-254.
55. Grant JA, White MV, Lee HH, et al. Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks. Allergy Asthma Proc. 2012;33:348-353.
56. Gower RG, Lumry WR, Davis-Lorton MA, et al. Current options for prophylactic treatment of hereditary angioedema in the United States: Patient-based considerations. Allergy Asthma Proc. 2012;33:235-240.
57. Bork K, Hardt J, Staubach-Renz P, et al. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: A retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112:58-64.
58. Szema AM, Paz G, Merriam L, et al. Modern preoperative and intraoperative management of hereditary angioedema. Allergy Asthma Proc. 2009;30:338-342.
59. Bernstein JA, Ritchie B, Levy RJ, et al. Population pharmacokinetics of plasmaderived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2010;105:149-154.
60. Martinez-Saguer I, Rusicke E, Aygoren-Pursun E, et al. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: A prospective study. Transfusion. 2010;50:354-360.
61. Craig T, Aygoren-Pursun E, Bork K, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J. 2012;5:182-199.
62. Betschel S, Badiou J, Binkley K, et al. Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol. 2014;10:50.
63. Gelfand JA, Sherins RJ, Alling DW, et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med. 1976;295:1444-1448.
64. Sheffer AL, Fearon DT, Austen KF. Methyltestosterone therapy in hereditary angioedema. Ann Intern Med. 1977;86:306-308.
65. Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol. 1981;68:181-187.
66. Church JA. Oxandrolone treatment of childhood hereditary angioedema. Ann Allergy Asthma Immunol. 2004;92:377-378.
67. Davis PJ, Davis FB, Charache P. Longterm therapy of hereditary angioedema (HAE). Preventive management with fluoxymesterone and oxymetholone in severely affected males and females. Johns Hopkins Med J. 1974;135:391-398.
68. Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of impeded androgen (oxymetholone) therapy of hereditary angioedema. J Allergy Clin Immunol. 1979;64:275-280.
69. Ott HW, Mattle V, Hadziomerovic D, et al. Treatment of hereditary angioneurotic oedema (HANE) with tibolone. Clin Endocrinol (Oxf). 2007;66:180-184.
70. Agostoni A, Cicardi M, Martignoni GC, et al. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. J Allergy Clin Immunol. 1980;65:75-79.
71. Drouet C, Desormeaux A, Robillard J, et al. Metallopeptidase activities in hereditary angioedema: Effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol. 2008;121:429-433.
72. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: A long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008;100:153-161.
73. Riedl MA. Critical appraisal of androgen use in hereditary angioedema: A systematic review. Ann Allergy Asthma Immunol. 2015;114:281-8.e7.
74. Cicardi M, Bergamaschini L, Cugno M, et al. Long-term treatment of hereditary angioedema with attenuated androgens: A survey of a 13-year experience. J Allergy Clin Immunol. 1991;87:768-773.
75. Szegedi R, Szeplaki G, Varga L, et al. Long-term danazol prophylaxis does not lead to increased carotid intima-media thickness in hereditary angioedema patients. Atherosclerosis. 2008;198:184-191.
76. Banerji A, Sloane DE, Sheffer AL. Hereditary angioedema: A current stateof-the-art review, V: Attenuated androgens for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol. 2008;100:S19-22.
77. Crampon D, Barnoud R, Durand M, et al. Danazol therapy: An unusual aetiology of hepatocellular carcinoma [letter]. J Hepatol. 1998;29:1035-1036.
78. Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J Hepatol. 2002;36:707-709.
79. Farkas H, Czaller I, Csuka D, et al. The effect of long-term danazol prophylaxis on liver function in hereditary angioedema-a longitudinal study. Eur J Clin Pharmacol. 2010;66:419-426.
80. Rahal S, Gilabert M, Ries P, et al. Hepatocellular carcinoma in a noncirrhotic liver after long-term use of danazol for hereditary angioedema. Case Rep Oncol. 2014;7:825-827.
81. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med. 1996;334:1630-1634.
82. Zuraw BL, Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med. 2012;125:938.e1-7.
83. Gandhi PK, Gentry WM, Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: Investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy. 2012;32:902-909.
84. Frank MM, Sergent JS, Kane MA, et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A doubleblind study. N Engl J Med. 1972;286:808-812.
85. Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med. 1972;287:452-454.
86. Kleniewski J, Blankenship DT, Cardin AD, et al. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med. 1992;120:129-139.
87. Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost. 2001;86:714-715.
88. Woo KS, Tse LK, Woo JL, et al. Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy. Br J Clin Pract. 1989;43:465-466.
89. Lumry W, Manning ME, Hurewitz DS, et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. J Pediatr. 2013;162:1017-22.e1-2.
90. Kreuz W, Rusicke E, Martinez-Saguer I, et al. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion. 2012;52:100-107.
91. Abdel-Karim O, Dizdarevic A, Bygum A. Hereditary angioedema: Children should be considered for training in self-administration. Pediatr Dermatol. 2014;31:e132-e135.
92. Farkas H, Varga L, Szeplaki G, et al. Management of hereditary angioedema in pediatric patients. Pediatrics. 2007;120: E713-e722.
93. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. J Allergy Clin Immunol. 2004;114:629-637.
94. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: Consensus document. Clin Exp Immunol. 2005;139:379-394.
95. Suffritti C, Zanichelli A, Maggioni L, et al. High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency. Clin Exp Allergy. 2014;44:1503-1514.
96. Defendi F, Charignon D, Ghannam A, et al. Enzymatic assays for the diagnosis of bradykinin-dependent angioedema. PLoS One. 2013;8(8):e70140.